Achillion Pharmaceuticals (NASDAQ:ACHN) Lowered to “Sell” at ValuEngine

ValuEngine downgraded shares of Achillion Pharmaceuticals (NASDAQ:ACHN) from a hold rating to a sell rating in a research note released on Thursday, ValuEngine reports.

Several other equities analysts have also recently weighed in on ACHN. Zacks Investment Research cut shares of Achillion Pharmaceuticals from a hold rating to a sell rating and set a $4.75 price objective on the stock. in a research report on Tuesday, August 27th. BidaskClub cut shares of Achillion Pharmaceuticals from a hold rating to a sell rating in a research report on Thursday. Four investment analysts have rated the stock with a sell rating and one has given a buy rating to the stock. The stock currently has an average rating of Sell and an average price target of $3.63.

Shares of NASDAQ ACHN traded down $0.04 during trading on Thursday, hitting $3.95. The company had a trading volume of 17,442 shares, compared to its average volume of 975,929. The company has a market cap of $557.36 million, a P/E ratio of -7.84 and a beta of 1.63. Achillion Pharmaceuticals has a 52 week low of $1.29 and a 52 week high of $5.03. The business’s 50-day moving average is $4.45 and its 200 day moving average is $3.26.



Achillion Pharmaceuticals (NASDAQ:ACHN) last posted its quarterly earnings results on Thursday, August 8th. The biopharmaceutical company reported ($0.14) earnings per share (EPS) for the quarter, meeting the Thomson Reuters’ consensus estimate of ($0.14). As a group, equities research analysts expect that Achillion Pharmaceuticals will post -0.59 earnings per share for the current fiscal year.

Several hedge funds have recently added to or reduced their stakes in the stock. Nuveen Asset Management LLC acquired a new position in Achillion Pharmaceuticals during the 2nd quarter worth $7,805,000. UBS Group AG grew its stake in Achillion Pharmaceuticals by 48.6% during the second quarter. UBS Group AG now owns 5,575,528 shares of the biopharmaceutical company’s stock worth $14,942,000 after buying an additional 1,824,534 shares during the last quarter. Mak Capital One LLC grew its stake in Achillion Pharmaceuticals by 33.5% during the first quarter. Mak Capital One LLC now owns 6,929,653 shares of the biopharmaceutical company’s stock worth $20,512,000 after buying an additional 1,738,053 shares during the last quarter. Morgan Stanley grew its stake in shares of Achillion Pharmaceuticals by 1,077.0% during the second quarter. Morgan Stanley now owns 831,397 shares of the biopharmaceutical company’s stock valued at $2,228,000 after purchasing an additional 760,761 shares during the last quarter. Finally, Renaissance Technologies LLC grew its stake in shares of Achillion Pharmaceuticals by 31.9% during the second quarter. Renaissance Technologies LLC now owns 3,007,000 shares of the biopharmaceutical company’s stock valued at $8,059,000 after purchasing an additional 728,000 shares during the last quarter. 78.57% of the stock is owned by institutional investors and hedge funds.

Achillion Pharmaceuticals Company Profile

Achillion Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, discovers, develops, and commercializes small molecule drug therapies for immune system disorders. Its lead drug candidate is ACH-4471, an inhibitor of factor D that is Phase II clinical trials for patients with paroxysmal nocturnal hemoglobinuria (PNH) and C3 glomerulopathy/immune complex membranoproliferative glomerulonephritis.

Featured Article: Trading Strategy Methods and Types

To view ValuEngine’s full report, visit ValuEngine’s official website.

Receive News & Ratings for Achillion Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Achillion Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.